Cargando…

Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis

BACKGROUND: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiebe, Jens, Ndrepepa, Gjin, Kufner, Sebastian, Lahmann, Anna L., Xhepa, Erion, Kuna, Constantin, Voll, Felix, Gosetti, Rosanna, Laugwitz, Karl‐Ludwig, Joner, Michael, Kastrati, Adnan, Cassese, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955304/
https://www.ncbi.nlm.nih.gov/pubmed/33410332
http://dx.doi.org/10.1161/JAHA.120.018304
_version_ 1783664221305700352
author Wiebe, Jens
Ndrepepa, Gjin
Kufner, Sebastian
Lahmann, Anna L.
Xhepa, Erion
Kuna, Constantin
Voll, Felix
Gosetti, Rosanna
Laugwitz, Karl‐Ludwig
Joner, Michael
Kastrati, Adnan
Cassese, Salvatore
author_facet Wiebe, Jens
Ndrepepa, Gjin
Kufner, Sebastian
Lahmann, Anna L.
Xhepa, Erion
Kuna, Constantin
Voll, Felix
Gosetti, Rosanna
Laugwitz, Karl‐Ludwig
Joner, Michael
Kastrati, Adnan
Cassese, Salvatore
author_sort Wiebe, Jens
collection PubMed
description BACKGROUND: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontinuation or DAPT after percutaneous coronary intervention with stenting. METHODS AND RESULTS: We performed a meta‐analysis of aggregate data from randomized clinical trials enrolling participants receiving a percutaneous coronary intervention with stenting and assigned to either early aspirin discontinuation or DAPT. Scientific databases were searched from inception through March 30, 2020. Trial‐level hazard ratios (HRs) and 95% CIs were pooled using a random effects model with inverse variance weighting. The primary outcome was all‐cause death. Secondary outcomes were myocardial infarction, stent thrombosis, stroke, and major bleeding. Overall, 36 206 participants were allocated to either early aspirin discontinuation (experimental therapy, n=18 088) or DAPT (control therapy, n=18 118) in 7 trials. Median follow‐up was 12 months. All‐cause death occurred in 2.5% of patients assigned to experimental and 2.9% of patients assigned control therapy (hazard ratio [HR], 0.91, 95% CI, 0.75–1.11; P=0.37). Overall, patients treated with experimental versus control therapy showed no significant difference in terms of myocardial infarction (HR, 1.02 [0.85–1.22], P=0.81), stent thrombosis (HR, 1.02 [0.87–1.20], P=0.83), or stroke (HR, 1.01 [0.68–1.49], P=0.96). However, the risk for major bleeding (HR, 0.58 [0.43–0.77], P<0.01) was significantly reduced by experimental as compared with control therapy. CONCLUSIONS: In patients treated with percutaneous coronary intervention and stenting, assigned to a strategy of early aspirin discontinuation versus DAPT, the risk of death and ischemic events is not significantly different but the risk of bleeding is lower.
format Online
Article
Text
id pubmed-7955304
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79553042021-03-17 Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis Wiebe, Jens Ndrepepa, Gjin Kufner, Sebastian Lahmann, Anna L. Xhepa, Erion Kuna, Constantin Voll, Felix Gosetti, Rosanna Laugwitz, Karl‐Ludwig Joner, Michael Kastrati, Adnan Cassese, Salvatore J Am Heart Assoc Systematic Review and Meta‐analysis BACKGROUND: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontinuation or DAPT after percutaneous coronary intervention with stenting. METHODS AND RESULTS: We performed a meta‐analysis of aggregate data from randomized clinical trials enrolling participants receiving a percutaneous coronary intervention with stenting and assigned to either early aspirin discontinuation or DAPT. Scientific databases were searched from inception through March 30, 2020. Trial‐level hazard ratios (HRs) and 95% CIs were pooled using a random effects model with inverse variance weighting. The primary outcome was all‐cause death. Secondary outcomes were myocardial infarction, stent thrombosis, stroke, and major bleeding. Overall, 36 206 participants were allocated to either early aspirin discontinuation (experimental therapy, n=18 088) or DAPT (control therapy, n=18 118) in 7 trials. Median follow‐up was 12 months. All‐cause death occurred in 2.5% of patients assigned to experimental and 2.9% of patients assigned control therapy (hazard ratio [HR], 0.91, 95% CI, 0.75–1.11; P=0.37). Overall, patients treated with experimental versus control therapy showed no significant difference in terms of myocardial infarction (HR, 1.02 [0.85–1.22], P=0.81), stent thrombosis (HR, 1.02 [0.87–1.20], P=0.83), or stroke (HR, 1.01 [0.68–1.49], P=0.96). However, the risk for major bleeding (HR, 0.58 [0.43–0.77], P<0.01) was significantly reduced by experimental as compared with control therapy. CONCLUSIONS: In patients treated with percutaneous coronary intervention and stenting, assigned to a strategy of early aspirin discontinuation versus DAPT, the risk of death and ischemic events is not significantly different but the risk of bleeding is lower. John Wiley and Sons Inc. 2021-01-07 /pmc/articles/PMC7955304/ /pubmed/33410332 http://dx.doi.org/10.1161/JAHA.120.018304 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Systematic Review and Meta‐analysis
Wiebe, Jens
Ndrepepa, Gjin
Kufner, Sebastian
Lahmann, Anna L.
Xhepa, Erion
Kuna, Constantin
Voll, Felix
Gosetti, Rosanna
Laugwitz, Karl‐Ludwig
Joner, Michael
Kastrati, Adnan
Cassese, Salvatore
Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
title Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
title_full Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
title_fullStr Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
title_full_unstemmed Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
title_short Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
title_sort early aspirin discontinuation after coronary stenting: a systematic review and meta‐analysis
topic Systematic Review and Meta‐analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955304/
https://www.ncbi.nlm.nih.gov/pubmed/33410332
http://dx.doi.org/10.1161/JAHA.120.018304
work_keys_str_mv AT wiebejens earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT ndrepepagjin earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT kufnersebastian earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT lahmannannal earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT xhepaerion earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT kunaconstantin earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT vollfelix earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT gosettirosanna earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT laugwitzkarlludwig earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT jonermichael earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT kastratiadnan earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis
AT cassesesalvatore earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis